Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Birth Defects Research. Part A, Clinical and Molecular Teratology|April 5, 2013
Commonality in Down and fetal alcohol syndromesJeffrey P Solzak, Yun Liang, Feng C Zhou, et al.NPJ Breast Cancer|July 8, 2017
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapyYu-Hsiang Chen, Bradley A Hancock, Jeffrey P Solzak, et al.NPJ Breast Cancer|June 27, 2017
Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancerJeffrey P Solzak, Rutuja V Atale, Bradley A Hancock, et al.Mammalian Genome : Official Journal of the International Mammalian Genome Society|September 29, 2011
Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65DnLaura G Reinholdt, Yueming Ding, Griffith J Gilbert, et al.British Journal of Cancer|January 15, 2016
A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomasMilan Radovich, Jeffrey P Solzak, Bradley A Hancock, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast CancerMilan Radovich, Jeffrey P Solzak, Chao J Wang, et al.Breast Cancer Research : BCR|August 7, 2019
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancersBradley A Hancock, Yu-Hsiang Chen, Jeffrey P Solzak, et al.Breast Cancer Research and Treatment|December 3, 2013
Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencingMilan Radovich, Susan E Clare, Rutuja Atale, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2021
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast CancerBryan P Schneider, Guanglong Jiang, Tarah J Ballinger, et al.JAMA Oncology|July 10, 2020
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical TrialMilan Radovich, Guanglong Jiang, Bradley A Hancock, et al.Pageof 1